Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.190
+0.015 (0.69%)
At close: Dec 20, 2024, 4:00 PM
2.210
+0.020 (0.91%)
After-hours: Dec 20, 2024, 7:33 PM EST
Esperion Therapeutics Revenue
Esperion Therapeutics had revenue of $51.63M in the quarter ending September 30, 2024, with 52.00% growth. This brings the company's revenue in the last twelve months to $295.45M, up 187.12% year-over-year. In the year 2023, Esperion Therapeutics had annual revenue of $116.33M with 54.14% growth.
Revenue (ttm)
$295.45M
Revenue Growth
+187.12%
P/S Ratio
1.23
Revenue / Employee
$1,231,046
Employees
240
Market Cap
431.51M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 116.33M | 40.86M | 54.14% |
Dec 31, 2022 | 75.48M | -2.97M | -3.79% |
Dec 31, 2021 | 78.45M | -149.10M | -65.52% |
Dec 31, 2020 | 227.55M | 79.18M | 53.37% |
Dec 31, 2019 | 148.36M | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Emergent BioSolutions | 1.13B |
Health Catalyst | 302.06M |
Sonida Senior Living | 253.20M |
Treace Medical Concepts | 202.86M |
SIGA Technologies | 173.73M |
MaxCyte | 45.60M |
Verve Therapeutics | 24.40M |
OmniAb | 20.41M |
ESPR News
- 3 days ago - Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions - GlobeNewsWire
- 7 days ago - Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone + - Seeking Alpha
- 8 days ago - Esperion Announces $210 Million Convertible Debt Financing - GlobeNewsWire
- 9 days ago - Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel - GlobeNewsWire
- 13 days ago - Will The Long Awaited Breakout For Esperion Therapeutics Hold? - Seeking Alpha
- 4 weeks ago - Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 - GlobeNewsWire
- 5 weeks ago - Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy - Seeking Alpha
- 6 weeks ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire